Peptide Comparison
Angiotensin (1-7)vsBPC-157
The heart-friendly peptide that balances your blood pressure and protects your cardiovascular system
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
Angiotensin (1-7)
0.5-1 mcg/kg–5-10 mcg/kg mcg
BPC-157
250–500 mcg
Frequency
Angiotensin (1-7)
Once daily
BPC-157
Once daily
Administration
Angiotensin (1-7)
As directed by healthcare provider
BPC-157
Subcutaneous injection
Cycle Length
Angiotensin (1-7)
Ongoing/indefinite
BPC-157
4-6 weeks
Onset Speed
Angiotensin (1-7)
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
Angiotensin (1-7)
Moderate human trials (Phase 1-2)
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Heart Health & Protection
Blood Pressure Balance
Anti-Inflammatory Support
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
Angiotensin (1-7)
Molecular Formula
C41H62N12O11
Molecular Weight
899.02 g/mol
Half-Life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
Varies by route of administration
CAS Number
25016-41-7
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
Angiotensin (1-7)
BPC-157
Applications
Best
suited for
Angiotensin (1-7)
Cardiovascular health and heart protection
Angiotensin (1-7) is particularly well-suited for individuals focused on cardiovascular health and heart protection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Blood pressure management and hypertension
Angiotensin (1-7) is particularly well-suited for individuals focused on blood pressure management and hypertension. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery from heart-related conditions
Angiotensin (1-7) is particularly well-suited for individuals focused on recovery from heart-related conditions. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory support
Angiotensin (1-7) is particularly well-suited for individuals focused on anti-inflammatory support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
Angiotensin (1-7)
Common
- Hypotension (Low Blood Pressure)
- Dizziness or Lightheadedness
- Injection Site Reactions
- Headache
Serious
- Hyperkalemia (High Potassium)
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
Angiotensin (1-7)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Angiotensin (1-7) is not FDA-approved and has no completed human clinical trials, with all safety data limited to animal studies and in vitro mechanistic work. Animal studies suggest potential benefits in hypertension and cardiac remodeling but also reveal risks of hypotension, particularly with concurrent ACE inhibitor or ARB therapy. The peptide's effects on systemic inflammation and immune function in animal models are not validated in humans. No pharmacokinetic data exists defining safe doses, optimal delivery routes, or organ accumulation patterns in humans.
Contraindications
- xSevere hypotension or uncontrolled low blood pressure
- xAcute myocardial infarction in early stages
- xConcurrent use with certain ACE inhibitors without medical supervision
- xPregnancy and breastfeeding (insufficient safety data)
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose Angiotensin (1-7) if...
- Cardiovascular health and heart protection
- Blood pressure management and hypertension
- Recovery from heart-related conditions
- Anti-inflammatory support
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health